A Phase II, Randomised Pilot Study to Evaluate the Efficacy and Safety of Subcutaneous, Bioresorbable Afamelanotide Implants and Narrow-Band Ultraviolet B (NB-UVB) Light in the Treatment of Nonsegmental Vitiligo Studio pilota di Fase II randomizzato, finalizzato alla valutazione dell' efficacia e sicurezza degli impianti sottocutanei bioriassorbibili di afamelanotide e della luce ultravioletta B a banda stretta (NB-UVB) nel trattamento dei pazienti affetti da vitiligine non segmentale

Trial Profile

A Phase II, Randomised Pilot Study to Evaluate the Efficacy and Safety of Subcutaneous, Bioresorbable Afamelanotide Implants and Narrow-Band Ultraviolet B (NB-UVB) Light in the Treatment of Nonsegmental Vitiligo Studio pilota di Fase II randomizzato, finalizzato alla valutazione dell' efficacia e sicurezza degli impianti sottocutanei bioriassorbibili di afamelanotide e della luce ultravioletta B a banda stretta (NB-UVB) nel trattamento dei pazienti affetti da vitiligine non segmentale

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Feb 2014

At a glance

  • Drugs Afamelanotide (Primary)
  • Indications Vitiligo
  • Focus Therapeutic Use
  • Sponsors Clinuvel Pharmaceuticals
  • Most Recent Events

    • 03 Feb 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top